Analyst Michael Okunewitch from Maxim Group maintained a Buy rating on Lineage Therap and keeping the price target at $3.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Michael Okunewitch’s rating is based on several promising developments within Lineage Cell Therapeutics. The company has reported progress in its DOSED study, which is evaluating the safety and efficacy of its delivery device across various settings. This study has already dosed its first patient and is expected to expand to a second site by the end of 2025. Additionally, Lineage’s collaboration with Roche on the OpRegen program, which is focused on optimizing delivery for geographic atrophy, underscores the potential of their therapies.
Lineage’s financial position also supports the Buy rating, as the company ended the quarter with $42.3 million in cash, providing a runway into the first quarter of 2027. The potential for additional collaboration agreements and milestone payments from Roche could further extend this financial runway. Furthermore, the OPC1 program, which targets spinal cord injuries, continues to show promise with recent advancements in its formulation and delivery system, enhancing its potential efficacy and safety profile.
According to TipRanks, Okunewitch is an analyst with an average return of -14.1% and a 33.79% success rate. Okunewitch covers the Healthcare sector, focusing on stocks such as ATAI Life Sciences, Lineage Therap, and Ocugen.